ABBV closed Tuesday at $244.78, down 4% from the July 10 close cited in last week's note — and the Street's response has been to keep raising targets anyway.
The analyst upgrade wave that defined last week's story has continued into this week, with two more target lifts arriving Monday and Tuesday. Citigroup's Geoff Meacham raised his target to $260 from $230 this morning, maintaining Neutral. UBS made the identical move yesterday — $260 from $230, also staying at Neutral. Those two neutrals are notable because they represent the cautious wing of the Street catching up on valuation, even without flipping constructive on the rating. The mean target now stands near $267, against a stock trading at $244.78, leaving roughly 9% implied upside from the consensus. Bulls at BMO ($300), Wells Fargo ($295), and Piper Sandler ($298) sit in a separate tier, pricing in a much larger re-rating into and after the July 27 Q2 print. The core debate is a familiar one: bears concede the immunology franchise is working — Skyrizi and Rinvoq script growth has been consistent — but point to the stock's valuation and the concentration risk around two products. Bulls argue the diversified pipeline, including the Cerevel neuroscience assets and ImmunoGen oncology additions, is underpriced at current levels. Forward EPS estimates rank in the 99th percentile for year-on-year increase, which is the kind of number that tends to force target revisions upward regardless of what a rating says.
The positioning picture around the July 27 earnings is notably unburdened. Short interest has dropped sharply — down nearly 13% on the week and almost 20% over the past month, to just 1.1% of free float. That's a low and falling short base entering a catalyst. Borrow availability is essentially unconstrained, with over a billion shares available to lend and cost to borrow running below 0.5%, so there is no friction in the lending market and no squeeze pressure in either direction. Options traders are leaning toward calls rather than puts: the put/call ratio is running at 0.71, more than one standard deviation below its 20-day average of 0.78, and near the lower end of its 52-week range. That is a moderately bullish options tilt. The ORTEX short score has drifted lower all week, from 31.6 at the start of July to 30.5 today — a direction that reflects covering rather than fresh shorting.
AbbVie's two most recent quarterly earnings prints are relevant context for anyone sizing a position into the July 27 release. The April 29 report produced a 6.9% single-day gain and extended to a 3.7% gain over the following five days — a clean beat-and-raise reaction. The May 8 print was effectively flat on the day, with a 3.8% gain over the week. Neither reaction produced outsized volatility, and neither hurt. The setup for July 27 is a stock that has already moved 7.5% higher over the past month, entering results from a slightly lower point after this week's pullback, with a lighter short base than at any point in recent months, and an options market tilting toward calls. Among closely watched sector peers, VRTX fell nearly 9% on the week and ALKS dropped 6.6%, suggesting the broader biotech space has seen more pressure than ABBV absorbed — which itself is worth tracking as a relative-strength signal going into the report.
The question heading into July 27 is less whether the immunology business is growing — the Street is broadly aligned that it is — and more whether the guidance raise is large enough to justify the targets that have just been set.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
